BioSpace News Archive

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, announced the initiation of a Phase 1/2 investigator-sponsored trial of evorpacept, a next generation CD47 blocker, in combination with rituximab and lenalidomide for the treatment of patients with indolent and aggressive non-Hodgkin lymphoma.

Aravive, Inc., a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D., Chief Medical Officer of Aravive, will participate in a virtual fireside chat at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 30, 2021 at 9:20 AM ET.

Hyperfine, Inc. is proud to announce that The Ohio State University Wexner Medical Center is deploying two Swoop™ systems in the emergency room, and the Comprehensive Stroke Center operating room.

Vifor Pharma Group and Travere Therapeutics, Inc. announced the companies have entered into a joint collaboration and licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand.

Permanent artificial skin is generally used in case of burn victims with superficial, deep, or partial wounds and chronic & acute wounds.

Significant growth in the issues pertaining to fertility across the globe is expected to work as one of the key drivers for the development of global egg donation market during the forecast period 2021–2031.

A blood pressure cuff is commonly used in combination with blood pressure monitor during blood pressure measurement procedures.

Solutions from the global artificial intelligence in genomics market are widely used in precision medicine as well as drug discovery branches of the healthcare and pharmaceutical industries.

Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced the presentation of data from a Phase 1 study to assess the safety, tolerability, and activity of oral paclitaxel and encequidar in combination with pembrolizumab in patients with advanced solid malignancies.

Transgene announces the presentation of data from a Phase I study combining intravenous oncolytic virus TG6002 and oral 5-FC in patients with advanced gastrointestinal carcinomas at the European Society for Medical Oncology virtual meeting taking place from September 16-21, 2021.